Header Logo

Connection

SUSAN ABUGHOSH to Humans

Back to Details
This is a "connection" page, showing publications SUSAN ABUGHOSH has written about Humans.
SUSAN ABUGHOSH
Connection Strength
0.950
Humans
  1. Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug na?ve type 2 diabetes patients. J Diabetes Complications. 2025 Sep; 39(9):109080.
    View in: PubMed
    Score: 0.025
  2. Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
    View in: PubMed
    Score: 0.025
  3. Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
    View in: PubMed
    Score: 0.025
  4. Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with atrial fibrillation. J Am Pharm Assoc (2003). 2025 May-Jun; 65(3):102355.
    View in: PubMed
    Score: 0.025
  5. Real-world treatment patterns in drug na?ve type 2 diabetes population: Initial combination therapy vs. sequential step-therapy. J Am Pharm Assoc (2003). 2025 Jan-Feb; 65(1):102295.
    View in: PubMed
    Score: 0.024
  6. Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
    View in: PubMed
    Score: 0.024
  7. Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
    View in: PubMed
    Score: 0.024
  8. Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation. J Manag Care Spec Pharm. 2024 May; 30(5):408-419.
    View in: PubMed
    Score: 0.023
  9. Trajectories of adherence to ACEI/ARB medications following a motivational interviewing intervention among Medicare Advantage beneficiaries in Texas. Patient Educ Couns. 2024 Feb; 119:108073.
    View in: PubMed
    Score: 0.022
  10. A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes. Drugs Aging. 2023 04; 40(4):377-390.
    View in: PubMed
    Score: 0.021
  11. Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling. High Blood Press Cardiovasc Prev. 2022 Nov; 29(6):601-610.
    View in: PubMed
    Score: 0.021
  12. Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study. Int J Clin Pharm. 2022 Aug; 44(4):966-974.
    View in: PubMed
    Score: 0.020
  13. Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
    View in: PubMed
    Score: 0.020
  14. Adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments among older patients. J Am Pharm Assoc (2003). 2022 Jul-Aug; 62(4):1351-1358.
    View in: PubMed
    Score: 0.020
  15. Interventions to improve medication adherence in inflammatory bowel disease: A systematic review. Patient Educ Couns. 2022 07; 105(7):1731-1742.
    View in: PubMed
    Score: 0.019
  16. Using group-based trajectory modeling to characterize the association of past ACEIs/ARBs adherence with subsequent statin adherence patterns among new statin users. J Am Pharm Assoc (2003). 2021 Nov-Dec; 61(6):829-837.e2.
    View in: PubMed
    Score: 0.019
  17. Evaluating perceptions of social determinants of health and Part D star performance of Medicare Advantage-contracted primary care providers serving a South Texas market. J Manag Care Spec Pharm. 2021 May; 27(5):544-553.
    View in: PubMed
    Score: 0.019
  18. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. J Manag Care Spec Pharm. 2021 Feb; 27(2):186-197.
    View in: PubMed
    Score: 0.019
  19. Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications. Patient Educ Couns. 2021 07; 104(7):1756-1764.
    View in: PubMed
    Score: 0.018
  20. Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
    View in: PubMed
    Score: 0.018
  21. Patient-reported barriers to statin adherence: Excerpts from a?motivational interviewing intervention in older adults. J Am Pharm Assoc (2003). 2021 Jan-Feb; 61(1):60-67.e1.
    View in: PubMed
    Score: 0.018
  22. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
    View in: PubMed
    Score: 0.018
  23. Evaluating trajectories of statin adherence after a motivational interviewing intervention. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):892-898.
    View in: PubMed
    Score: 0.018
  24. Evaluating Success Factors of a Medication Adherence Tracker Pilot Program in Improving Part D Medication Adherence Metrics in a Medicare Advantage Plan: Importance of Provider Engagement. J Manag Care Spec Pharm. 2020 May; 26(5):662-667.
    View in: PubMed
    Score: 0.018
  25. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020 Apr; 99(16):e19603.
    View in: PubMed
    Score: 0.017
  26. Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. J Manag Care Spec Pharm. 2019 Oct; 25(10):1053-1062.
    View in: PubMed
    Score: 0.017
  27. Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
    View in: PubMed
    Score: 0.017
  28. Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review. Expert Rev Cardiovasc Ther. 2019 Jun; 17(6):427-434.
    View in: PubMed
    Score: 0.016
  29. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
    View in: PubMed
    Score: 0.016
  30. A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence. J Manag Care Spec Pharm. 2017 May; 23(5):549-560.
    View in: PubMed
    Score: 0.014
  31. Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers. Arch Psychiatr Nurs. 2017 02; 31(1):62-67.
    View in: PubMed
    Score: 0.014
  32. Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. Subst Use Misuse. 2016; 51(5):586-97.
    View in: PubMed
    Score: 0.013
  33. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2016 Jan; 22(1):63-73.
    View in: PubMed
    Score: 0.013
  34. Intention to quit water pipe smoking among Arab Americans: Application of the theory of planned behavior. J Ethn Subst Abuse. 2017 Jan-Mar; 16(1):80-90.
    View in: PubMed
    Score: 0.013
  35. Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Subst Use Misuse. 2015; 50(13):1628-37.
    View in: PubMed
    Score: 0.013
  36. The relationship between obesity and prescription of smoking cessation medications. Popul Health Manag. 2014 Jun; 17(3):172-9.
    View in: PubMed
    Score: 0.012
  37. Predictors of smoking cessation medication use among nonobese and obese smokers. Subst Use Misuse. 2014 May; 49(6):752-61.
    View in: PubMed
    Score: 0.011
  38. The social norms and beliefs of teenage male electronic cigarette use. J Ethn Subst Abuse. 2013; 12(4):300-7.
    View in: PubMed
    Score: 0.011
  39. Ethnicity and waterpipe smoking among US students. Int J Tuberc Lung Dis. 2012 Nov; 16(11):1551-7.
    View in: PubMed
    Score: 0.010
  40. Differences in obesity management among physicians. Popul Health Manag. 2012 Oct; 15(5):287-92.
    View in: PubMed
    Score: 0.010
  41. Cigarette smoking among Jordanian adults. J Ethn Subst Abuse. 2012; 11(2):101-12.
    View in: PubMed
    Score: 0.010
  42. Waterpipe smoking among students in one US university: predictors of an intention to quit. J Am Coll Health. 2012; 60(7):528-35.
    View in: PubMed
    Score: 0.010
  43. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy. 2005 Dec; 25(12):1729-35.
    View in: PubMed
    Score: 0.006
  44. Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
    View in: PubMed
    Score: 0.006
  45. Does Concomitant Psychostimulants Mitigate Second-Generation Antipsychotics-Associated Weight Gain? An Observational Study Based on Electronic Medical Records Data. J Child Adolesc Psychopharmacol. 2025 Nov; 35(9):508-517.
    View in: PubMed
    Score: 0.006
  46. Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
    View in: PubMed
    Score: 0.006
  47. Racial and Ethnic Disparities in Access to Care Among Adults with Cardiovascular Disease. J Health Care Poor Underserved. 2025; 36(1):96-114.
    View in: PubMed
    Score: 0.006
  48. Racial and Ethnic Disparities in Perceived Health Status Among Patients With Cardiovascular Disease. Prev Chronic Dis. 2024 Nov 14; 21:E89.
    View in: PubMed
    Score: 0.006
  49. Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data. Pharmacotherapy. 2024 Oct; 44(10):782-793.
    View in: PubMed
    Score: 0.006
  50. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm. 2004 Sep-Oct; 10(5):404-11.
    View in: PubMed
    Score: 0.006
  51. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.006
  52. Racial and Ethnic Disparity in Healthcare Expenditure and Resource Utilization Among Patients with Cardiovascular Diseases. J Racial Ethn Health Disparities. 2025 Oct; 12(5):3210-3222.
    View in: PubMed
    Score: 0.006
  53. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer. 2024 Jun 04; 32(7):407.
    View in: PubMed
    Score: 0.006
  54. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
    View in: PubMed
    Score: 0.006
  55. Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2024 05; 34(4):201-209.
    View in: PubMed
    Score: 0.006
  56. Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents. J Clin Psychopharmacol. 2024 Mar-Apr 01; 44(2):124-132.
    View in: PubMed
    Score: 0.006
  57. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.006
  58. Development and internal validation of a risk prediction model for HIV disease severity among people living with HIV and mental illness or substance use disorder. Ann Epidemiol. 2023 11; 87:79-92.
    View in: PubMed
    Score: 0.006
  59. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.006
  60. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.005
  61. Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic. Int J Clin Pharm. 2023 Dec; 45(6):1396-1404.
    View in: PubMed
    Score: 0.005
  62. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
    View in: PubMed
    Score: 0.005
  63. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
    View in: PubMed
    Score: 0.005
  64. Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
    View in: PubMed
    Score: 0.005
  65. Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior. Subst Use Misuse. 2022; 57(12):1761-1771.
    View in: PubMed
    Score: 0.005
  66. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
    View in: PubMed
    Score: 0.005
  67. Association of Puberty Stage and Weight Status with Cardiometabolic Risk in Children and Adolescents Living on the Texas-Mexico Border. Metab Syndr Relat Disord. 2022 10; 20(8):440-450.
    View in: PubMed
    Score: 0.005
  68. Effect of inadequate care on diabetes complications and healthcare resource utilization during management of type 2 diabetes in the United States. Postgrad Med. 2022 Jun; 134(5):494-506.
    View in: PubMed
    Score: 0.005
  69. Perception Regarding Knowledge of COVID-19 Prevention in a Sample of a Middle Eastern and North African (MENA) Community in Houston, Texas, USA. Int J Environ Res Public Health. 2022 01 04; 19(1).
    View in: PubMed
    Score: 0.005
  70. Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine. J Am Pharm Assoc (2003). 2021 Sep-Oct; 61(5):589-595.
    View in: PubMed
    Score: 0.005
  71. Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD. J Atten Disord. 2022 Feb; 26(3):370-376.
    View in: PubMed
    Score: 0.005
  72. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
    View in: PubMed
    Score: 0.004
  73. Drug Enforcement Administration Rescheduling of Hydrocodone Combination Products Is Associated With Changes in Physician Pain Management Prescribing Preferences. J Pain Palliat Care Pharmacother. 2019 Mar - Jun; 33(1-2):22-31.
    View in: PubMed
    Score: 0.004
  74. Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 06; 53(6):612-620.
    View in: PubMed
    Score: 0.004
  75. Effect of coverage gap on healthcare utilization among Medicare beneficiaries with chronic obstructive pulmonary disorder. Curr Med Res Opin. 2019 02; 35(2):321-328.
    View in: PubMed
    Score: 0.004
  76. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
    View in: PubMed
    Score: 0.004
  77. Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach. Res Social Adm Pharm. 2017 May - Jun; 13(3):503-512.
    View in: PubMed
    Score: 0.003
  78. Smoking Cessation Support Among Oncology Practitioners in a Regional Cancer Center in the Middle East-Improving a Critical Service for Cancer Care. Oncologist. 2016 Apr; 21(4):503-5.
    View in: PubMed
    Score: 0.003
  79. Evaluating Pharmacist-Written Recommendations to Providers in a Medicare Advantage Plan: Factors Associated with Provider Acceptance. J Manag Care Spec Pharm. 2016 Jan; 22(1):49-55.
    View in: PubMed
    Score: 0.003
  80. The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics. J Public Health Manag Pract. 2015 Sep-Oct; 21(5):467-76.
    View in: PubMed
    Score: 0.003
  81. CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol. 2015 Apr; 38(2):165-73.
    View in: PubMed
    Score: 0.003
  82. Predictors of smoking among male college students in Saudi Arabia. East Mediterr Health J. 2013 Nov; 19(11):909-14.
    View in: PubMed
    Score: 0.003
  83. Modeling covariates of self-perceived and epidemiologic notions of risk for acquiring STIs/HIV among military personnel: a comparative analysis. AIDS Behav. 2013 Mar; 17(3):1159-75.
    View in: PubMed
    Score: 0.003
  84. Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses. 2012 May; 28(5):454-9.
    View in: PubMed
    Score: 0.002
  85. Correlates of HIV knowledge and sexual risk behaviors among female military personnel. AIDS Behav. 2010 Dec; 14(6):1401-14.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.